Firering Strategic Minerals: From explorer to producer. Watch the video here.
Anyone else confirm what they are seeing with their broker.
+6.02% up / 11.18p to buy small amounts.
I sincerely hope no long/medium term holders were shaken into selling yesterday, especially by random posts on here. If there was actual bad news I could understand but this was never case.
Well said Chippyjo, whilst not happy with the fall, I felt no reason to panic and like you added/topped up.
Only wish I had more capital to buy at these prices.
Investors/traders happy to buy at these prices it seems then.
So do we conclude the earlier selling off was options related? If so what is the exact scenario?
Don't forget increased cash runway/payments possibly received by Genmab.
Yet the doomies want to play this as company going under. Lol.
@AB - Are you agreeing with my thoughts now?
Good point Dalestar, it was a very quiet/low volume day yesterday, so no knee jerk reaction straight after the end/interview, so as you say today's slide is down to actual selling/volume, which again as you say is hopefully related to Lindy raising funds for the options.
@ab1234 - you can take my post/implications however you want, but as dalestar said, another opaque, vague RNS followed by a somewhat contradictory interview, the company will be fully aware of this pattern you'd think. I was wondering about Prof. Durrant options also. All IMO.
Also Douve87's post, like Dalestars, sums it perfectly.
@dalestar, agree. I wonder how deliberate this is though?
Thanks ๐
...about the situation regarding Prof. Durrants options and the July date.
Does yesterdays RNS have any affect?
So how many companies do Scancell have direct links with now, is that 7 or 8?
Taken from Marcusl2's post from the other side:
When talking about GenMab :
"
She also touches on progress in the relationship with Genmab (CSE:GEN) since signing a commercial licensing agreement last year, and clarifies that Scancell is continuing to pursue other such deals: "We've just signed an evaluation with a new company... and we're in current discussions with a second company about another potential deal."
"
So how many companies is that now? Are those the same ones mentioned in the RNS?
@ab1234
Do you "hope" the wider market interprets Professor Durrant closing (and argubly mandatory/obvious) interview comments about funding as negatively as you have?
AB124 - so that's the one thing you took away from the interview?
Lol why I am not surprised.
On that particular subject what about the potential income from other agreements?
I somehow(!) glossed over this, but separately, and perhaps more importantly:
"....The platform has generated revenues and the antibodies continue to yield compelling results which have led to a new 6-month evaluation by a leading Biotech company."
Who could this be? Is 6 months typically long enough to make an appraisal/bid?
Either way, Scancell/Scancells products are clearly (and have been) in the rifle scopes of big pharma.
P.s. which 'cell therapy company ' do we think this is? Did someone mention BioNtech? Or GenMab?
"Additional in-house data has illustrated the potential of our antibodies as chimeric antigen receptor T cell (CART) therapies providing the data for a deal with a cell therapy company."
I've had to re-read this a few times:
"...providing data for a deal"
Not a "potential" deal, not a proposed deal, not an interested party wanting to assess, but an actual deal with a specific cell therapy company? There is no ambiguity there, is there? Are they saying once data is delivered, and assuming it's good, the deal will be done?
"Additional in-house data has illustrated the potential of our antibodies as chimeric antigen receptor T cell (CART) therapies providing the data for a deal with a cell therapy company"
IMO the key statement in today's RNS.
"10/7/2023
08:57 chillpill: I thought this part was interesting. Looks like we can expect further licensing deals here:
The platform has generated revenues and the antibodies continue to yield compelling results which have led to a new 6-month evaluation by a leading Biotech company. Additional in-house data has illustrated the potential of our antibodies as chimeric antigen receptor T cell (CART) therapies providing the data for a deal with a cell therapy company. These results along with updates on SCIB1 and Modi-1 will be presented at the AACR-CIMT meeting in Milan in September 2023."
"10/7/2023
09:00 markingtime: One point on that. I read that as being a 6 month investigation of the whole platform, not just a component."
So that conference in Milan, either way looks to be a significant one and does it imply a the deal will coincide at the same time too?